Erlotinib ‘dosing-to-rash’: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer

BACKGROUND: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mita, A C, Papadopoulos, K, de Jonge, M J A, Schwartz, G, Verweij, J, Mita, M M, Ricart, A, Chu, Q S-C, Tolcher, A W, Wood, L, McCarthy, S, Hamilton, M, Iwata, K, Wacker, B, Witt, K, Rowinsky, E K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185947/
https://www.ncbi.nlm.nih.gov/pubmed/21878940
http://dx.doi.org/10.1038/bjc.2011.332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185947/
https://www.ncbi.nlm.nih.gov/pubmed/21878940
http://dx.doi.org/10.1038/bjc.2011.332

Ejemplares similares